Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies
- PMID: 20951511
- DOI: 10.1016/j.drugalcdep.2010.06.022
Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies
Abstract
Background: Existing trials of varenicline have typically excluded smokers with concurrent medical and psychiatric illnesses and no data exist comparing effectiveness of varenicline with combination pharmacotherapy. This study evaluated abstinence and psychiatric outcomes of various tobacco dependence medications, including varenicline.
Methods: Retrospective cohort of 723 smokers, most with significant medical and psychiatric comorbidity, was evaluated at the UMDNJ-Tobacco Dependence Clinic from 2006 to 2008. Demographics, measures of tobacco dependence and co-morbidities, and a validated instrument measuring psychological distress (Kessler-6) were obtained. Primary outcome was 7-day point abstinence at 6 months after target quit date.
Results: Cessation medications used included combination pharmacotherapy (39%), single nicotine replacement therapy (NRT) or bupropion (29%), and varenicline (23%), with 9% using no medications. Overall, 23% of patients were abstinent at 6 months. In an adjusted regression model, smokers using varenicline or combination medications were more likely abstinent at 6 months than those using no medications (adjusted odds ratio=2.99; 95% confidence interval=1.20-7.47 and 2.80; 1.15-6.82, respectively), but not statistically higher than those using single medications (AOR=1.70). Age, gender, education, marital status, cigarettes per day, time to first cigarette, night smoking, and menthol smoking were not significantly related to abstinence. Varenicline or combination medications did not significantly increase serious psychological distress over the treatment period compared to other medication options.
Conclusions: Both varenicline and combination pharmacotherapy were effective and did not increase psychological distress for up to 6 months in smokers with co-morbidities treated at a specialty clinic.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Varenicline and bupropion sustained-release combination therapy for smoking cessation.Nicotine Tob Res. 2009 Mar;11(3):234-9. doi: 10.1093/ntr/ntn031. Epub 2009 Feb 25. Nicotine Tob Res. 2009. PMID: 19246427 Clinical Trial.
-
Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications.Nicotine Tob Res. 2012 Sep;14(9):1035-9. doi: 10.1093/ntr/nts001. Epub 2012 Feb 17. Nicotine Tob Res. 2012. PMID: 22345320
-
Pharmacotherapy and smoking cessation at a tobacco dependence clinic.Prev Med. 2006 Feb;42(2):114-9. doi: 10.1016/j.ypmed.2005.11.013. Epub 2005 Dec 20. Prev Med. 2006. PMID: 16375954
-
[Smoking reduction and temporary abstinence: new approaches for smoking cessation].J Mal Vasc. 2003 Dec;28(5):293-300. J Mal Vasc. 2003. PMID: 14978435 Review. French.
-
Smoking cessation: an overview of treatment options with a focus on varenicline.Pharmacotherapy. 2007 Nov;27(11):1550-7. doi: 10.1592/phco.27.11.1550. Pharmacotherapy. 2007. PMID: 17963463 Review.
Cited by
-
Predicted Impact of Nicotine Reduction on Smokers with Affective Disorders.Tob Regul Sci. 2015 Jul;1(2):154-165. doi: 10.18001/TRS.1.2.5. Tob Regul Sci. 2015. PMID: 26236765 Free PMC article.
-
Healthcare Costs of Smokers Using Varenicline Versus Nicotine-Replacement Therapy Patch in the United States: Evidence from Real-World Practice.Adv Ther. 2019 Feb;36(2):365-380. doi: 10.1007/s12325-018-0858-y. Epub 2018 Dec 19. Adv Ther. 2019. PMID: 30569324 Free PMC article.
-
Use of Mentholated Cigarettes and Likelihood of Smoking Cessation in the United States: A Meta-Analysis.Nicotine Tob Res. 2020 Mar 16;22(3):307-316. doi: 10.1093/ntr/ntz067. Nicotine Tob Res. 2020. PMID: 31204787 Free PMC article. Review.
-
Effectiveness of varenicline versus nicotine replacement therapy for smoking cessation with minimal professional support: evidence from an English population study.Psychopharmacology (Berl). 2014 Jan;231(1):37-42. doi: 10.1007/s00213-013-3202-x. Epub 2013 Jul 20. Psychopharmacology (Berl). 2014. PMID: 23873417
-
Assessing the evidence on the differential impact of menthol versus non-menthol cigarette use on smoking cessation in the U.S. population: a systematic review and meta-analysis.Subst Abuse Treat Prev Policy. 2021 Aug 11;16(1):61. doi: 10.1186/s13011-021-00397-4. Subst Abuse Treat Prev Policy. 2021. PMID: 34380503 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical